Navigation Links
The Huntington Study Group announces first-HD study
Date:6/21/2013

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada. The trial is sponsored by Auspex Pharmaceuticals, Inc. who is developing the drug for the treatment of Huntington disease, as well as Tourette syndrome and tardive dyskinesia.

First-HD is a randomized, double blind, placebo controlled study that examines the efficacy, safety and tolerability of a formulation of the investigational drug known as SD-809 for the treatment of chorea associated with Huntington Disease. The drug has the same mechanism of action as the FDA approved drug tetrabenazine that is used to lessen chorea in people with HD, an inherited disease that affects over 30,000 people in both the United States and Canada. HD is characterized by brain cell death that usually begins between the ages of 30 to 50. This cell loss results in motor, cognitive and behavioral signs and symptoms. Chorea, which is characterized by involuntary movements, is a hallmark of the disease.

Because SD-809 is more slowly metabolized than tetrabenazine, it provides more consistent and predictable drug levels and can be given less often than tetrabenazine. With these changes, a lower overall dose of SD-809 can be administered and it may be more convenient for persons with HD. This study will test the efficacy, safety and tolerability of a formulation of SD-809 in the management of chorea symptoms in HD patients who have not previously taken tetrabenazine. Participants will be involved in this trial for approximately 4 months.

Dr. Samuel Frank, the Principal Investigator of First-HD notes that "we are excited to work with Auspex to investigate the efficacy, safety and tolerability of this interesting and innovative new treatment for Huntington disease. We have few treatment options for Huntington disease, and only one for chorea. We hope this is a step forward in addressing this large unmet need for our patients."

There is no cost to participate in First-HD. Individuals with a diagnosis of HD who are interested in participating in First-HD should visit the HSG website: http://www.huntington-study-group.org or call toll free: 1(800) 487-7671 (North America). More information regarding this trial can also be found at http://clinicaltrials.gov


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Huntingtons Disease Linked to Reduced Cancer Risk in Study
2. Researchers restore neuron function to brains damaged by Huntingtons disease
3. Reach2HD, a Phase II study in Huntingtons disease, launched
4. Device implanted in brain has therapeutic potential for Huntingtons disease
5. Proposed drug may reverse Huntingtons disease symptoms
6. Well-known author and historian reports on progress in Huntingtons therapies
7. Human model of Huntingtons disease created from skins stem cells
8. Scientists Use Stem Cells to Mimic Huntingtons Disease
9. First Huntingtons disease center established in Washington, D.C., area
10. Cell loss in the brain relates to variations in individual symptoms in Huntingtons disease
11. NIH funds UT Dallas study on cause of Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology: